Keytruda
Overview
Keytruda is an immuno-oncology drug developed by Merck (MSD) in the United States, and its active ingredient is pembrolizumab. It is a humanized monoclonal antibody that binds to the PD-1 receptor, blocking the pathway by which cancer cells evade the immune system and helping T cells attack tumors. Since FDA approval in the United States in 2014, it has rapidly expanded its indications and joined the ranks of the world's top-selling medicines, becoming a standard therapy for various solid tumors, including non-small cell lung cancer, melanoma, and triple-negative breast cancer.
Key details
Mechanism of action
Keytruda binds to the PD-1 (Programmed Death-1) receptor on the surface of T cells and blocks its interaction with ligands (PD-L1/PD-L2) expressed by tumor cells or immunosuppressive cells. Normally, the PD-1–PD-L1 pathway acts as a 'brake' that suppresses immune responses, and cancer cells exploit this to evade immune attack. Keytruda reactivates T cell-mediated antitumor immunity by releasing this brake. For this reason, it is classified as an immune checkpoint inhibitor.
Indications
It was initially approved as a treatment for advanced melanoma, but its indications have since expanded greatly to include non-small cell lung cancer, head and neck squamous cell carcinoma, Hodgkin lymphoma, urothelial carcinoma, gastric cancer, cervical cancer, hepatocellular carcinoma, triple-negative breast cancer, and colorectal cancer (MSI-H/dMMR). Depending on biomarkers such as PD-L1 expression or MSI-H (microsatellite instability-high solid tumors), it is used as monotherapy or combination therapy.
Administration and safety
It is generally administered as an intravenous infusion every 3 or 6 weeks. Representative adverse reactions are immune-related adverse events, and rash, thyroid dysfunction, pneumonitis, colitis, and hepatitis have been reported. Because of its mechanism of activating the immune system, it can also cause inflammation in normal tissues, so discontinuation of administration and steroid treatment are required if severe adverse events occur.
Market and clinical standing
Keytruda is a representative example of a 'pipeline in a brand' with dozens of indications and accounts for a large share of Merck's sales. It has demonstrated improved overall survival (OS) in numerous phase 3 trials and is leading the immuno-oncology drug market.
Latest trends
As of 2024–2025, with patent expiration approaching (the active ingredient patent around 2028), competition to develop biosimilars is in full swing, and attempts are underway to improve administration convenience through the development of a subcutaneous (SC) formulation. In addition, clinical trials expanding indications to perioperative adjuvant therapy and early-stage cancer are active, and research on combination strategies with mRNA vaccines and antibody-drug conjugates (ADC) is actively underway. In Korea as well, reimbursement coverage has been gradually expanded for major cancer types such as lung cancer and gastric cancer.
Related topics
- [[Immuno-oncology drugs]]
- [[PD-1 inhibitors]]
- [[Pembrolizumab]]
- [[Non-small cell lung cancer]]
- [[Biosimilars]]
- [[Merck (MSD)]]